Si-bone, Inc.
SI-BONE, Inc., a medical device company, focuses on solving musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. The company offers proprietary minimally invasive surgical implant systems to address sacroiliac joint dysfunction and degeneration, adult deformity and degeneration, and pelvic trauma, as well as implantable bone products. It also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with a proprietary 3D-printed porous surface and fenestrated design; iFuse TORQ, a line of 3D-printed threaded implants designed for applications in pelvic trauma and sacroliliac fusion; and iFuse Bedrock Granite Implant System that provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion; and iFuse TORQ TNT to treat pelvic trauma and sacroiliac joint dysfunction, as well as iFuse INTRA implants that are marketed as human cells, tissues, and cellular or tissue-based products. The company markets its products primarily with a direct sales force, as well as through third-party sales agent and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
Analysis Summary
Simultaneously, SI-BONE and Mr. Wolf entered into a 12-month consulting agreement, effective from November 6, 2025. Under this agreement, Mr. Wolf will provide consulting services to support the Company's efforts in marketing, strategy, business development, and other corporate matters. Key terms of the agreement include the acceleration of vesting for 8,675 shares of restricted stock units granted to Mr. Wolf on June 5, 2025, making them fully vested as of November 6, 2025. Additionally, he will receive cash compensation at an hourly rate for services rendered. This arrangement suggests a strategic decision to transition Mr. Wolf's involvement from a direct board role to a specialized advisory capacity, retaining his expertise for critical business functions. The absence of financial metrics, revenue, earnings, or guidance in this specific report means a comprehensive financial analysis of Q4 2025 is not possible based on the provided transcript.
Key Highlights
- • Daniel Wolf resigned from the Board of Directors on November 6, 2025.
- • His resignation was amicable and not due to any disagreement.
- • The Board of Directors decreased its size from nine to eight members.
- • Thomas A. West was appointed to the Board's Audit Committee.
- • Daniel Wolf entered a 12-month consulting agreement for marketing, strategy, and business development.
- • The consulting agreement includes accelerated vesting of 8,675 restricted stock units and hourly cash compensation.
Financial Metrics
Stock Performance (90 Days)
Positive Signals
- • Retention of former director's expertise through a consulting agreement.
- • Amicable nature of the director's departure.
- • Board streamlining through reduction in size.
- • Appointment of a current director to the Audit Committee.
Risks & Concerns
- — Lack of Q4 2025 financial performance data in this specific filing.
- — Potential for increased consulting expenses from the new agreement.
- — Changes in board composition and governance structure.
- — Reliance on a consultant for key strategic areas like marketing and business development.
Full Transcript
Recent Si-bone, Inc. News
Stock Price
Company Info
- Website
- si-bone.com
- Industry
- Medical Devices
- Sector
- Healthcare
- Headquarters
- Santa Clara, CA, United States
- CEO
- Ms. Laura A. Francis MBA
- Employees
- 349
Layoff Stats
- Layoff Events
- 0
- Total Affected
- 0
Recent Layoffs
No canonical layoff events recorded for this company.